oseltamivir has been researched along with sphingosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, SC; Fremgen, DM; Hatta, M; Jatzek, A; Kawaoka, Y; Oldstone, MB; Rosen, H; Shinya, K; Suresh, M; Teijaro, JR; Walsh, KB; Watanabe, T; Wilker, PR | 1 |
| Arish, M; Naz, F | 1 |
2 other study(ies) available for oseltamivir and sphingosine
| Article | Year |
|---|---|
Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.
Topics: Alternaria; Animals; Bronchoalveolar Lavage Fluid; Cell Line; Cytokines; Dogs; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunomodulation; Influenza A virus; Male; Mice; Mice, Inbred C57BL; Neutralization Tests; Orthomyxoviridae Infections; Oseltamivir; Sphingosine | 2011 |
Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy?
Topics: Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Humans; Indans; Influenza A Virus, H1N1 Subtype; Lysophospholipids; Mice; Orthomyxoviridae Infections; Oseltamivir; Oxadiazoles; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sphingosine; Sphingosine-1-Phosphate Receptors | 2020 |